Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures



Status:Completed
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:7/13/2018
Start Date:June 2011
End Date:January 2012

Use our guide to learn which trials are right for you!

This chronic, prospective, non-randomized feasibility study is designed to evaluate the
Integrated Patient Care (IPC) concept in subjects who already have either a Medtronic
Chronicle Implantable Hemodynamic Monitor (IHM) or Chronicle Implantable Cardioverter
Defibrillator (ICD) device implanted, and are currently enrolled in the Chronicle Offers
Management to Patients with Advanced Signs & Symptoms of Heart Failure (COMPASS-HF) Extension
Phase Study (IDE # G020304). The purpose of the study is to use daily cardiac filling
pressures from the Chronicle device to provide timely medication adjustments (diuretics) to
subjects.

Subjects will be asked to transmit to the CareLink Network daily. Data specific to this study
(subject's daily estimated Pulmonary Arterial Diastolic (ePAD) pressure values) will be
extracted from the CareLink database and transferred to the IPC clinician website.

As each subject is enrolled, clinicians at each participating site will determine the
appropriate target pressure range for each subject based on a review of the subject's
pressure data. Each day after enrollment, the subject's current pressure data will be
compared to a target pressure range that the clinician sets for that subject.

The patient instruction set (PtIS) is limited to a daily diuretic prescription and associated
supplements, per physician discretion. The PtIS should not include adjustments of non-heart
failure medications and should not include heart failure medications that are not indicated
for day-to-day adjustments (e.g. ACE-Inhibitors, Angiotensin Receptor Blockers (ARBs), and
Beta-Blockers). The PtIS will be sent from the IPC clinician website to the subject through a
Patient Home Monitor.

Inclusion Criteria:

- Patients implanted with a Chronicle IHM device (Model 9520, Model 9520B) or Chronicle
ICD device (Model 7286)

- Patients who have been prescribed daily diuretic therapy for the management of heart
failure

- Patients currently participating in the COMPASS-HF Extension Phase Study (IDE
#G020304)

- Patients willing and able to give informed consent

Exclusion Criteria:

- Patients with non-physiologic Right Ventricular (RV) pressure values

- Patients who have diuretic resistance

- Patients who have an estimated Glomerular Filtration Rate(eGFR) <30 ml/min (recorded
within the last six months)

- Patients who have a Chronicle IHM device (Model 9520) that was implanted as part of
the Pulmonary Arterial Hypertension (PAH) Pilot Study (IDE #G020303)

- Patients who do not have the ability to actively participate in the management of
their own heart failure care (determine by physician discretion)(e.g. patient does not
have ability to operate study equipment, patient does not have a history of compliance
to sending CareLink transmissions)

- Patients who have a reasonable probability of needing a device replacement during the
study (approximately two months)

- Patients enrolled or planning to participate in a concurrent drug and/or device study
during the course of this clinical trial

- Patient who are pregnant (all females of child-bearing potential must have a negative
pregnancy test within 1 week of enrollment)
We found this trial at
3
sites
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Norfolk, Virginia 23507
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73120
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials